Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 02 Oct 2016
At a glance
- Drugs Capecitabine (Primary) ; CB 839 (Primary)
- Indications Colon cancer; Colorectal cancer; Rectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 09 Sep 2016 Planned number of patients changed from 47 to 53.
- 09 Sep 2016 Status changed from not yet recruiting to recruiting.
- 12 Aug 2016 New trial record